Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Peter Agron
Observed names:
Agron, Peter,
P Agron,
P. Agron,
PETER AGRON
Institutions:
Johnson & Johnson (United States),
Janssen Research & Development (United States)
Observed institutions:
Johnson & Johnson (United States),
Actelion (United States),
Janssen Scientific Affairs (United States),
Janssen Research & Development (United States)
OpenAlex ID:
A5025108178
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension
2024
·
Hilary M. DuBrock
, Tyler E. Wagner
, et al.
·
European Respiratory Journal
·
38
Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study
2020
·
Sandeep Sahay
, Yuen Tsang
, et al.
·
Pulmonary Circulation
·
10
PDF
Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data
2022
·
Marjolaine Gauthier-Loiselle
, Yuen Tsang
, et al.
·
Current Medical Research and Opinion
·
5
Macitentan in Pulmonary Hypertension (PH) Due to Chronic Lung Disease: Real-World Evidence from OPUS/OrPHeUS
2021
·
S. Sahay
, R. Channick
, et al.
·
The Journal of Heart and Lung Transplantation
·
2
PDF
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
2025
·
Richard Channick
, Sarah Medrek
, et al.
·
JHLT Open
·
1
PDF
Development and Evaluation of a Predictive Algorithm for Unsatisfactory Response Among Patients With Pulmonary Arterial Hypertension Using Health Insurance Claims Data
2021
·
MARJOLAINE GAUTHIER-LOISELLE
, YUEN TSANG
, et al.
·
CHEST Journal
·
1
PDF
Late Breaking Abstract - Exploratory analysis of a PDGFRB protein quantitative trait locus and seralutinib treatment response in the phase 3 PROSERA PAH study
2026
·
Robin Osterhout
, Raymond L. Benza
, et al.
Clinical characteristics, treatment patterns and healthcare resource utilisation for portopulmonary hypertension patients in the USA: a real-world study
2025
·
Hilary DuBrock
, Mark Small
, et al.
·
BMJ Open
A Comparison of Treatment Patterns and Healthcare Resource Utilization in Portopulmonary Hypertension and Idiopathic/hereditary Pulmonary Arterial Hypertension in the Usa
2021
·
HILARY DUBROCK
, MARK SMALL
, et al.
·
CHEST Journal
Real-world Clinical Presentation of Patients With Portopulmonary Hypertension in Comparison With Idiopathic/hereditary Pulmonary Arterial Hypertension in the Usa
2021
·
HILARY DUBROCK
, MARK SMALL
, et al.
·
CHEST Journal
PDF
慢性肺疾患による肺高血圧症(PH)におけるマシテンタン: OPUS/OrPHeUSからの実世界エビデンス【JST・京大機械翻訳】
2021
·
S Sahay
, R Channick
, et al.
·
The Journal of Heart and Lung Transplantation
Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry
2020
·
Hilary DuBrock
, Richard Channick
, et al.
Show more works
View as search
Works count:
14
Citation count:
57
H-index:
3
I10-index:
2
Year
Topic
Type